Physician profile
Rocco J Andreozzi
NPI 1386608164
$1,141.61
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $287 · 2021: $26.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $158.55 | 2019-2020 | |
| Abbvie INC. | $156.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.26 | 2019-2020 | |
| Pfizer INC. | $133.31 | 2019-2020 | |
| Allergan, INC. | $102.28 | 2020 | |
| Amgen INC. | $88.38 | 2019 | |
| Amarin Pharma, INC. | $84.28 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $68.90 | 2019-2020 | |
| Melinta Therapeutics, LLC | $67.47 | 2019 | |
| Daiichi Sankyo INC. | $61.02 | 2019-2020 | |
| Genentech USA, INC. | $23.68 | 2019 | |
| Astellas Pharma US INC | $16.80 | 2019 | |
| Shire North American Group INC | $14.25 | 2019 | |
| Glaxosmithkline, LLC. | $13.46 | 2019 | |
| Merck Sharp & Dohme LLC | $13.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocco Andreozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.